- Home
- OTLY vs DRTS Comparison
OTLY vs DRTS Comparison
Compare OTLY & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- DRTS
- Stock Information
- Founded
- OTLY 1994
- DRTS 2015
- Country
- OTLY Sweden
- DRTS Israel
- Employees
- OTLY N/A
- DRTS N/A
- Industry
- OTLY Packaged Foods
- DRTS Medical/Dental Instruments
- Sector
- OTLY Consumer Staples
- DRTS Health Care
- Exchange
- OTLY Nasdaq
- DRTS Nasdaq
- Market Cap
- OTLY 303.5M
- DRTS 256.2M
- IPO Year
- OTLY 2021
- DRTS N/A
- Fundamental
- Price
- OTLY $17.79
- DRTS $3.21
- Analyst Decision
- OTLY Buy
- DRTS Strong Buy
- Analyst Count
- OTLY 5
- DRTS 1
- Target Price
- OTLY $19.25
- DRTS $9.00
- AVG Volume (30 Days)
- OTLY 143.0K
- DRTS 60.6K
- Earning Date
- OTLY 07-23-2025
- DRTS 08-11-2025
- Dividend Yield
- OTLY N/A
- DRTS N/A
- EPS Growth
- OTLY N/A
- DRTS N/A
- EPS
- OTLY N/A
- DRTS N/A
- Revenue
- OTLY $828,200,000.00
- DRTS N/A
- Revenue This Year
- OTLY $4.68
- DRTS N/A
- Revenue Next Year
- OTLY $4.78
- DRTS N/A
- P/E Ratio
- OTLY N/A
- DRTS N/A
- Revenue Growth
- OTLY 4.43
- DRTS N/A
- 52 Week Low
- OTLY $6.00
- DRTS $2.11
- 52 Week High
- OTLY $20.80
- DRTS $4.39
- Technical
- Relative Strength Index (RSI)
- OTLY 64.37
- DRTS 52.03
- Support Level
- OTLY $16.90
- DRTS $3.03
- Resistance Level
- OTLY $18.23
- DRTS $3.58
- Average True Range (ATR)
- OTLY 0.93
- DRTS 0.20
- MACD
- OTLY -0.04
- DRTS -0.01
- Stochastic Oscillator
- OTLY 78.27
- DRTS 38.33
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.